NEWS

January 7, 2019

Coherus BioSciences Secures $75 Million Credit Financing with HealthCare Royalty Partners

November 2, 2018

U.S. FDA Approves UDENYCA™ (pegfilgrastim-cbqv)

October 23, 2018

Gary A. Lyons Joins HealthCare Royalty Partners Senior Advisor Board

September 25, 2018

Coherus Biosciences Receives European Commission Approval for UDENYCA™ (Pegfilgrastim Biosimilar)

May 24, 2018

Portola Pharmaceuticals Receives $100 Million Milestone Payment from HealthCare Royalty Partners for FDA Approval of Andexxa®

May 14, 2018

U.S. Food and Drug Administration Accepts and Acknowledges Coherus Biosciences Biologics License Application of CHS-1701 (Pegfilgrastim Biosimilar Candidate) For Review

May 10, 2018

La Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty Partners

May 4, 2018

U.S. FDA Approves Portola Pharmaceuticals’ Andexxa^®, First and Only Antidote for the Reversal of Factor Xa Inhibitors

April 19, 2018

HealthCare Royalty Partners Appoints Four New Partners

March 23, 2018

Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over